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Summary BMS-1 81174 is an aminodisulphide derivative of Mitomycin C (MMC) with activity against a range of tumour cell lines and
xenografts, including MMC-resistant tumours. In a phase I study of 82 patients with confirmed malignancy, we administered BMS-181174 at
doses of 0.8-75 mg m-2 by intravenous injection every 28 days. At least three patients were evaluated at each dose level, and 174 courses
were administered. The pharmacokinetics were dose linear at BMS-181174 doses of 11.5-75 mg m-2 and the drug appeared to undergo wide
distribution. The maximum-tolerated dose was 65 mg m-2 in previously treated patients and 75 mg m-2 in chemotherapy-naive cases. The
dose-limiting toxicity was myelosuppression, particularly thrombocytopenia, which was prolonged and cumulative. Three patients treated at
65-75 mg m-2 died suddenly with evidence of pneumonia/pneumonitis, thought to be drug-related. Other toxicities included thrombophlebitis,
possible cardiotoxicity (asymptomatic, reversible decline in left ventricular function) and renal impairment. The partial response rate was 5%
(4 out of 82) overall, and 9% (3 out of 32) in patients treated at 65-75 mg m-2. Responses occurred in treated and previously-untreated
patients, including cases of colorectal cancer, non-small-cell lung cancer, ovarian cancer and adenocarcinoma of unknown primary site. BMS-
181174 has anti-cancer activity but, because of its toxicity, particularly pneumonitis and thrombophlebitis, no phase 11 studies are planned.
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Mitomycin C (MMC) is an anti-tumour antibiotic that has clinical
activity against a broad spectrum of solid tumours. The dose-
limiting toxicity is myelosuppression, which is often prolonged and
cumulative. There have also been reports of pulmonary fibrosis,
nephrotoxicity and haemolytic-uraemic syndrome (Carter and
Crooke, 1979; Rabadi et al, 1982). MMC is cardiotoxic in animals
and in patients when given with or after doxorubicin (Dorr et al,
1992). The clinical use of MMC is limited by these toxicities and
by the emergence of drug resistance. This has led to a search for
derivatives ofMMC with a better therapeutic index. BMS-181174,
also known as BMY-25067, is a semi-synthetic analogue of MMC
created by substitution of the C6 amino group by a nitrophenyl
disulphide moiety (Figure 1). In vitro studies show that BMS-
181174 is active against MMC-resistant tumour cell lines and,
unlike MMC, is not more toxic in hypoxic than aerobic conditions
(Rockwell et al, 1995). BMS-181174-resistant bladder cancer cells
show significantly lower levels of DT-diaphorase, an enzyme
involved in bioreductive activation of MMC and hence implicated
also in BMS-181174 activation. However BMS-181174-resistant
cells display no alteration in levels of NADPH cytochrome P450
reductase, another MMC activation enzyme, nor in glutathione
(GSH) and GSH transferase, which reportedly affect the cytotoxi-
city ofMMC (Singh et al, 1995). These findings suggest that BMS-
181174 has different mechanisms of activation and anti-tumour
activity from the parent compound.
Preliminary in vitro studies indicated that BMS-181174 disap-
pears rapidly in plasma, presumably through disulphide exchange
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reactions between the N7-[2-thioethyl]-MMC (TEMMC) portion
of BMS-181174 and thiol-containing molecules. It is not known
what form of BMS-181174 enters cells. However, it is possible
that, after systemic administration, several forms of the drug in
addition to the parent compound may be present, including mixed
disulphides with endogenous thiols (such as cysteine, glutathione
and methionine), methylated TEMMC and TEMMC disulphide.
All ofthese compounds may have anti-tumour activity.
Preclinical testing of this and other MMC analogues indicated
that BMS-181174 caused myelosuppression and proteinuria. Of
three species tested (mice, rats and dogs), there was evidence of
dose-related cardiotoxicity in rats only (Bregman et al, 1989).
However, BMS-181174 was the least toxic MMC analogue tested
and was marginally less myelosuppressive than the parent
compound (Doyle and Vyas, 1990). In mice treated with a single
intravenous dose, theLDIO was 24.9 mg m-2. The dog was the most
sensitive animal species tested, showing myelosuppression at doses
corresponding to one-tenth the mouse LD,O. In the dog, the toxic
low dose (TLD) was 2.5 mg m-2 (Nicaise and Usakewicz, 1989).
The anti-tumour effects ofBMS-181174 have been evaluated in
vivo (Bradner et al, 1990). Compared with MMC, it had superior
activity against B16 melanoma when both drug and tumour were
given intraperitoneally, or when given intravenously against
subcutaneous tumour. After intraperitoneal treatment, its activity
was similar to that of MMC against ascitic P388 and L1210
leukaemias and M109 lung carcinoma in mice. BMS-181174 had
slight activity against a subline of L1210 that was partly resistant
to MMC, but it was inactive against highly MMC-resistant P388.
In these studies at their respective maximum non-lethal doses in
mice, BMS-181174 caused less neutropenia than MMC and was
also less neutropenic and much less thrombocytopenic in ferrets
(Bradner et al, 1990).
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Figure 1 Chemical structures of Mitomycin-C and BMS-181174
We have undertaken phase I evaluation of BMS-181174, to
assess the maximum-tolerated dose (MTD), toxicity and pharma-
cokinetic parameters of the drug after intravenous injection every
28 days. The selection of the starting dose for the clinical study
was based on the toxic low dose (TLD) in the dog. This proved to
be an underestimate of the dose range required for clinical use, as
became clear from clinical safety data, and it was necessary to
extend the clinical trial beyond the original projected maximum
dose levels of 20-40 mg m-2.
PATIENTS AND METHODS
Patients
Patients recruited to this phase I study had histologically proven
advanced cancer with WHO performance status (PS) 0-3 and life
expectancy of >8 weeks. None had radiotherapy or chemotherapy
within 4 weeks of treatment with BMS-181174. Patients were
excluded ifthey had received MMC, nitrosoureas or anthracycline
and also, after accrual of 14 patients, if they had had radio-
therapy to any part of the cardiac field. Other exclusion criteria
included elevated serum creatinine (>130 gmol 1-') or bilirubin
(>25,tmol 1-'), active infection, active cardiac disease, history of
myocardial infarct or abnormal left ventricular function (left
ventricular ejection fraction LVEF <50%, see below). Entry into
the study required total WBC count >4.0 x 1091-' and platelets
.100 x 109 1-'. Approval to conduct this study was granted by the
Local Research Ethical Committees of Oxford, UK, and Wirral,
UK, and each patient gave written informed consent.
Drug administration
BMS-181174 was supplied as lyophilized powder and was recon-
stituted in 10 ml of Tween 80 diluent to a final concentration of
2 mg ml-'. The solution was filtered through a 0.22-,u filter
(Millipore). All patients received prophylactic antiemetics
(dexamethasone and metoclopramide) before treatment, and these
were continued after treatment as required. Patients treated at
initial dose levels received a bolus injection over 2-5 min into the
tubing of an i.v. infusion of250 ml of5% dextrose in water. At and
above the 32 mg m-2 dose level, the drug was administered as a
slow i.v. injection over 30 min into the tubing of an infusion of
500 ml of 5% dextrose in water. The 5% dextrose infusion was
continued for 2 h after drug administration. The treatment was
repeated at the same dose (or at the preceding dose level if the
MTD had been reached for a given patient) every 4 weeks, or after
full recovery from adverse reactions. A minimum of three patients
were evaluated at each dose level, and at least 1 week elapsed
between entry of the first and next patients at each dose level.
Before treating patients at the higher dose level, at least 2 weeks
elapsed, with documentation ofreversibility oftoxicity.
BMS-181174 pharmacokinetics
In order to perform the pharmacokinetic study it was necessary to
develop a sensitive assay for the drug. The analytical method used
here measured total TEMMC, derived from BMS-181174 in vivo.
Samples for pharmacokinetic analysis were obtained, with
informed consent, immediately before the start of treatment and at
timed points afterwards. At dose levels 0.8-19 mg m-2, these
points were 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 8, 10 and 12 h.
Subsequently the timing of samples was changed because of the
change in drug administration (see above) and because ofprelimi-
nary information available from analysis of samples from patients
treated at lower dose levels. Thus from 32 mg m-2, the samples
were collected before dosage and at 30 min (end infusion), 35, 40,
45 min and 1, 1.25, 1.5, 2, 4, 8, 12, 18, 24 and 48 h afterwards. The
blood samples were collected into Vacutainer sample tubes
containing EDTA. Within 30 min of collection, the samples were
centrifuged at lOOg for 15 min at 5°C, and the plasma was stored
at -20°C. For sample analysis, disulphides of TEMMC were
reduced using tributylphosphine, and the resulting free thiol was
derivitized with maleimide to permit measurement of total
TEMMC. The analysis used a validated high performance liquid
chromatography (HPLC) assay with a lower limit of quantitation
of 50 ng ml-' (Gaver, 1995; LaCreta, 1995a). Plasma TEMMC
concentrations from the first nine patients were measured as
described by Gaver (1995). This method was modified and revali-
dated (LaCreta, 1995a) and used to measure TEMMC concentra-
tions from the remaining 19 patients. The changes in methodology
were considered to be minor and would not affect the interpreta-
tion of data from this study. The acceptance criteria for the
analysis of TEMMC in plasma specified that the coefficient of
determination (R2) for the standard linear regression curve should
exceed 0.99 and that the predicted concentrations of at least three-
quarters ofthe standards and two-thirds ofthe quality control (QC)
samples be within ±15% oftheir individual nominal concentration
values. Plasma concentration-time data for TEMMC, reported as
ng equivalent BMS-181 174 ml-', were analysed uying non-
compartmental methods (Gibaldi and Perrier, 1982) and were used
to derive the area under the concentration-time curve from zero to
infinity, AUC(INF), the terminal half-life (T,12), apparent total
clearance (CLT) and apparent steady-state volume of distribution
(1s/). Because the assay measured TEMMC and not BMS-181 174
itself, the values CLT and Vss were apparent values and were
calculated using the nominal dose ofBMS-181174.
Assessment of response
All patients underwent imaging investigations at trial entry to obtain
baseline tumour measurements. Investigations were repeated after
every two courses of BMS-181174 and on cessation of treatment.
Responses were defined by WHO criteria (WHO, 1979).
Assessment of toxicity
Patients were assessed before treatment and at weekly intervals
thereafter to check symptomatic toxicity, full blood count (FBC)
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Table 1 Patient characteristics
Number entered
Age (years)
Median
Range
Sex
Male
Female
Primary tumour site
Colorectal
Ovarian
Lung
Non-SCLC
SCLC
Unknown
Melanoma
Bladder
Breast
Gastric
Pancreas
Renal
Endometrium
Other
Previous treatment
Systemic therapy
Chemotherapy
Biological
Endocrine
Radiotherapy
Alone
With chemotherapy
None
82
59
20-73
42
40
21
17
11
1
8
3
3
2
2
2
2
3
7
52 (63%)
50
4 (Interferon 3, retinoid 1)
2
28 (34%)
10
18
20
and serum biochemistry, including urea, creatinine and liver
function tests. Before each course, patients underwent chest
radiography, electrocardiogram, echocardiography and creatinine
clearance, assessed by measurement of plasma and 24-h urine
creatinine. The ECG was repeated 60-120 min after each treat-
ment. At echocardiography, measurements were made of left
ventricular systolic and diastolic volumes, allowing calculation of
the left ventricular ejection fraction LVEF (Teichholtz et al, 1976;
Feigenbaum, 1994) as follows: LV diastolic volume - LV systolic
volume (i.e. stroke volume)/LV diastolic volume. All patients had
LVEF of .50% before starting treatment, and this was reassessed
before each course. A significant reduction in LVEF was defined
as a decline from the baseline value by .10% and taking the value
of below normal (50%), or a fall of .5% below 50% (i.e. <45%).
Other toxicities were graded using WHO criteria, and thrombo-
phlebitis was graded as follows: grade 1, local soreness at adminis-
tration site; 2, phlebitis with or without local discomfort; 3, severe
phlebitis making vein indurated and painful, and/or phleboscle-
rosis causing vein to close down during infusion; 4, deep vein
thrombosis requiring use of anticoagulants and discontinuation of
study drug.
RESULTS
We recruited 82 patients, 42 men and 40 women, to this phase I
study. The median age was 59 (range 20-73) years, and primary
diagnoses were as shown in Table 1. Ofthe 82 patients entered, 52
(63%) had previous systemic therapy and 28 (34%) prior radio-
therapy. We evaluated BMS-181174 at doses of0.8-75 mg m-2 and
between three and 20 patients were treated at each dose level
(Table 2). Four patients were able to complete six courses oftreat-
ment, and these were all treated at or below 9mg m-2. At
65 mg m-2, two of 12 patients received three courses (including
one whose third course was given at 75 mg m-2) and one had four
courses. At the highest dose level, 75 mg m-2, four patients had
three courses each and one patient received four courses. In two
patients, a first course ofBMS-181174 at 65 mg m-2 was followed
by grade 4 thrombocytopenia, and a second course was given at
55 mg m-2. Apart from these two cases, there were no dose reduc-
tions; patients remained on the same dose level until cessation of
this therapy.
Pharmacokinetic parameters
Samples for pharmacokinetic study were analysed on 28 patients
(see Table 3). All samples were analysed in a total of 23 analytical
sessions. The standard curves were linear over a 50-1250 ng ml-'
concentration range, and coefficients of determination were 0.987
or greater. For the original analytical method (Gaver, 1995), the
predicted QC concentrations for TEMMC were within ±7% of
Table 2 Treatment administered
Dose level No. of Prior No. of Courses per patient PK (no.
(mg/M-2) patients chemotherapy courses Median (range) assayed)
0.8 4 4 4 1 0
1.6 3 1 9 2 (1-6) 0
3.2 7 2 14 2(1-4) 3
5.0 5 5 12 2 (1-4) 2
7.5 5 4 12 2 (2-4) 4
11.5 7 5 21 2 (1-6) 3
19.0 8 6 16 1 (1-6) 3
32.0 5 3 9 2 (1-3) 3
50.0 6 4 13 2(1-4) 5
65.0 12 12 26a 2 (1-3) 1
75.0 20 6 38b 1 (1-4) 4
Total 82 52 174 35
alncludes one patient who had a first course at 65 mg m-2 followed by a second at 55 mg m-2. bincludes
one course given at 75 mg m-2 after two at 65 mg m-2. PK, pharmacokinetic parameters.
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Table 3 Pharmacokinetic parameters for N7-[2-thioethyl]-mitomycin C derived from BMS-181174 after a single intravenous dose of BMS-181174
Dose Infusion CMAX AUC(INF) T12 CLT VSS
(mg m-2) n rate (ng ml-') (ng h ml-') (h) (ml min-' m-2) (I m-2)
3.2 3 bolus 402+ 95.2a _b _ _
5.0 2 bolus 1239c - - - -
(730-1749)
7.5 4 bolus 1290 ± 298 - - - -
11.5 3 bolus 2239+ 114 8437±2771 7.05 + 2.49 23.6 ± 6.4 23.0+ 8.1
19 3 bolus 2928 ±502 8198 + 2783 7.37 ± 0.83 40.8 ± 11.6 17.9 + 1.5
32 3 30 min 5332 ±936 46 318+ 16 408 20.4 ± 6.38 12.4+ 4.1 17.4± 2.1
50 5 30 min 6727 +2096 32 792 ± 10 075 13.5 ± 3.06 27.7 ± 9.7 25.7 ± 8.0
65 1 30 min 6126 31 782 11.5 34.0 26.4
75 3 30 min 8173 +126 63 911 ± 21 853 19.6 15.3 21.7+7.1 27.7+ 19.3
aValues are mean + s.d. binsufficient data to calculate parameter. cValues are mean (range).
Table 4 Haematological toxicity of BMS-181174: worst WHO grade toxicity
Dose No. of Haemoglobin Neutrophils Platelets
patients
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4
0.8 4 2 1 1 3 1 4
1.6 3 2 1 3 3
3.2 7 2 2 2 1 7 7
5.0 5 2 1 2 5 5
7.5 5 3 2 5 5
11.5 7 3 3 1 7 7
19 8a 1 5 1 7 7
32 5 4 1 4 1 4 1
50 6 3 3 6 6
65 12 1 4 6 1 10 2 6 2 2 2
75-U 14 3 3 7 1 0 10 1 2 0 1 7 1 3 0 3
75-T 6 0 2 4 0 0 1 1 2 2 0 1 0 0 2 3
75-U, previously untreated patients at dose level 75 mg m-2; 75-T, patients who had received prior chemotherapy followed by BMS-181174 at dose level
75 mg m-2. aOne patient no data.
AUC
=0.74xdose + 1.95
r2=0.55 0
* 0
* _
.
0
3I3
0 10 20 30 40 50 60 70 80
Doses of BMS - 181174 (mg m-2)
Figure 2 Pharmacokinetics of total N7-[2-thioethyl]-MMC (TEMMC), derived from BMS-181174 in vivo. (A) Representative plasma concentration-time profile
of TEMMC from a patient receiving BMS-1 81174 at 65 mg m-2 via a 30-min intravenous infusion. (B) Assessment of dose linearity of TEMMC after
administration of BMS-181174
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their nominal value, the within day error was <9% relative stan-
dard deviation (RSD), and the between day error was <3% RSD.
For the modified analytical method, the predicted QC concentra-
tions for TEMMC were within ±9% of their nominal values, with
the exception of the 214 ng ml-' QC, which deviated by -20%.
This QC was made at the time ofthe twelfth analytical session and,
because of the large deviation, was replaced with a QC of 100 ng
ml-'. The overall within day error was <9% RSD, and the between
day error was <11% RSD. The QC data indicated adequate accu-
racy and precision during the analysis.
Several of the study samples for one patient at the 75 mg m-2
dose level appeared to be haemolysed. The plasma concentra-
tion-time profile fluctuated wildly, so a pharmacological analysis
was not performed. Thus, at the 75 mg m-2 dose level, the mean
pharmacokinetic parameters of the remaining three patients are
reported. The results are shown in Table 3. The assay was not
sufficiently sensitive to quantify plasma levels generated by treat-
ment at the 0.8 and 1.6 mg m-' dose levels. At dose levels of
3.2-7.5 mg m-2, there was insufficient data for pharmaco-
kinetic analysis, therefore only CMAX is reported (Table 3).
Pharmacokinetic data were obtained at doses of 11.5-75 mg m-'
At 11.5 and 19 mg m-2, the estimated T,12 was approximately 7 h.
Using the 30-min infusional schedule, the disappearance of
TEMMC from plasma appeared to be biphasic, with an initial
rapid distribution phase followed by a mean T,,2 ranging from 11.5
to 20.4 h. A representative plasma concentration-time curve of
TEMMC is shown in Figure 2A. The AUC(INF) increased in a
linear fashion with dose over the range 11.5-75 mg m-2 (Figure
2B). T,, apparent CLT and apparent Vss did not change in relation
to dose (Table 3). These findings suggest that the pharmaco-
kinetics of TEMMC are linear after the administration of BMS-
181174 doses ranging from 11.5 to 75 mg m-2. Mean apparent CLT
values ranged from 12.4 to 40.8 ml min-' m-2, and mean apparent
Vss values ranged from 17.4 to 27.71 m-. The apparent VSS of
TEMMC is equivalent to total body water, suggesting extensive
distribution ofTEMMC.
Toxicity
Haematological toxicity
Table 4 describes the haematological toxicity of BMS-181174.
Apart from the development of grade 2-3 anaemia in several
patients treated at 3.2-5 mg m-', which may have been at least in
part disease related, there was no significant (grade >3) haemato-
logical toxicity up to 50 mg m-' (see Table 4). Twelve patients, all
pretreated with chemotherapy, received BMS-181174 at dose level
65 mg m-. No grade 3 toxicity was seen at this dose level, but
grade 4 anaemia was seen in one case (8%) and thrombocytopenia
in two cases (17%), both of whom received prophylactic platelet
transfusion (see Figure 3 for illustration of one of these patients,
case 62). No patients at this dose level required broad-spectrum
intravenous antibiotics for neutropenic sepsis. Two patients had
intravenous cefuroxime in the absence ofevidence of neutropenia,
one for a chest infection and the second at his local hospital for a
severe episode of pneumonia/pneumonitis from which he died
(case 72, see below).
Of 20 patients treated at the highest dose level (75 mg m-2), 14
had no prior chemotherapy. In this group, grade 3-4 anaemia,
neutropenia and thrombocytopenia were experienced by one (7%),
one (7%) and three (21 %) patients respectively. Equivalent figures
for the six previously treated patients at this dose level were none,
BMS-181174
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Figure 3 Effect of BMY25067 on granulocyte and platelet counts. This
case shows worsening thrombocytopenia after successive courses of BMS-
181174 in a previously treated patient (case 62) with metastatic colorectal
cancer
Table 5 Thrombophlebitis caused by BMS-181174
Dose level No. of patients Thrombophlebitis, worst grade
(mg m-2)
0 1 2 3 4
0.8 4 4
1.6 3 3
3.2 7 7
5.0 5 5
7.5 5 3 1 1
11.5 7 5 1 1
19.0 8 7 1
32.0 5 2 1 2
50.0 6 6
65.0 12 7 0 4 1 1
75.0 20 12 0 3 3 2
two (33%) and five (83%) respectively. Thus, at this dose level, a
total ofeight patients had grade 4 thrombocytopenia, which neces-
sitated prophylactic platelet transfusion in four, treatment delay in
one case, dose reduction in another and cessation of treatment in
five cases. Similar to the previous dose level, neutropenia did not
present a problem and no patients required antibiotics for
neutropenic sepsis.
Nadir blood counts were experienced after a median of 15-22
days. At the highest dose level there did not appear to be a clini-
cally significant difference in time to nadir counts between previ-
ously treated and untreated patients (not shown). After treatment at
65 mg m-2, granulocyte counts recovered to normal in 34.5 days
(median) (range 27-42 days) and platelet counts in 25 days (range
21-45 days). Equivalent figures for recovery after treatment at
75 mg m-2 were 22.5 days (range 19-43) and 29.5 days (range
20-46), with no clinically significant difference between treated
and untreated patients. In patients receiving multiple courses, there
was a tendency for each successive course to be followed by a
more profound nadir, with a longer time to recovery (see Figure 3).
Thrombophlebitis
Of 31 patients treated at 7.5-50 mg m-2, eight (26%) had throm-
bophlebitis, although this was generally mild (grade 1-2; see
Table 5). However 7 out of 32 (22%) evaluable patients treated at
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Table 6 Cardiotoxicity: effect of BMS-181174 on LVEF
Dose No. of patients NE NC Reduction
0.8 4 3 1 0
1.6 3 1 1 1
3.2 7 0 5 2
5.0 5 1 3 1
7.5 5 0 5 0
11.5 7 2 5 0
19 8 3 5 0
32 5 1 3 1
50 6 2 3 1
65 12 3 9 0
75 20 4 13 3
Significant reduction in LVEF defined as decline from baseline LVEF by
>10% taking the value to below normal (50%), or a fall of >5% below normal
(i.e. <45%). NE, not evaluable; NC, no change.
Table 7 Responses to BMS-181174
Dose level No. of patients Response
(mg m-2)
NE PD SD MR PR
0.8 4 4
1.6 3 3
3.2 7 1 5 1
5.0 5 1 4
7.5 5 4 1
11.5 7 5 2
19.0 8 7 1
32.0 5 5
50.0 6 5 1
65.0 12 2 8 1 1
75.0 20 4 10 4 2
Total 82 10 59 8 1 4
NE, not evaluable; PD, progressive disease; SD, stable disease; MR, minor
response; PR, partial response.
65-75 mg m-2 experienced thrombophlebitis of grade 3-4. Three
of these had grade 4 thrombophlebitis, which presented in two
cases as axillary vein thrombosis leading to cessation of therapy.
The third patient (case 72, treated at 65 mg m-2) developed periph-
eral grade 3 thrombophlebitis after one course, and the second and
third were administered through a long line inserted via the
contralateral antecubital fossa. Acute dyspnoea developed on day
15, with ventilation/perfusion scan evidence of pulmonary
embolus (i.e. grade 4 toxicity). Despite anticoagulation and a
normal peripheral white blood count, he deteriorated with a radio-
logical picture offulminating pneumonitis (not confirmed microbi-
ologically), and he died on day 27 of course three. Permission for
post-mortem examination was declined by his family (see below,
Pulmonary toxicity).
Cardiotoxicity
Table 6 shows the effects of BMS-181174 on LVEF. Twenty
patients who received only one course of BMS-181174 were not
evaluable because they did not undergo repeat LVEF assessment.
In one patient treated at 1.6 mg m-2, the LVEF fell from 63%
pretreatment to 35% after three courses, recovering to 53% 3
months after the sixth course. This patient had previously under-
gone radiotherapy to a paratracheal mass; subsequently, we
excluded patients who had received chest radiotherapy involving
the cardiac field.
Significant reduction in LVEF was seen in 9 out of 62 (15%)
evaluable patients, including individual patients treated at most
dose levels between 1.6 and 65 mg m-2 and three of sixteen evalu-
able patients (19%) treated at 75 mg m-2 (Table 6). Overall, there
was no indication of a relationship with dose or cumulative dose
for this toxicity. The nadir LVEF value was observed after a
median of two courses (range one to six courses). Of the nine
patients experiencing a drop in LVEF, four had repeat echocardio-
graphy, which showed recovery of left ventricular function in I
week to 3 months. In one patient, a second course oftreatment was
delayed for 2 weeks until the LVEF had recovered, and, in the
remaining three, treatment was discontinued for other reasons.
Table 8 Reasons for stopping treatment
Dose level No. of patients Reasons for stopping treatment
(mg m-2)
PDa Toxicity Completed
six courses
Haematological Lung Thrombophlebitis/ Other
thrombosis
0.8 4 4
1.6 3 2 1
3.2 7 7
5.0 5 5
7.5 5 5
11.5 7 5 2
19.0 8 7 1
32.0 5 4 1 1
50.0a 6 5 2
65.0a 12 10 1 1 1 1
75.0a 20 12 6 3 2 2
alncludes death on treatment.
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The change in LVEF was asymptomatic in all patients, with the
exception ofone who developed grade 3 dyspnoea 3 months after a
single course of BMS-181174 at 75 mg m-2. This patient had a
normal chest radiograph and an echocardiogram that showed septal
hypertrophy with an LVEF of 45% compared with 66% pretreat-
ment. The patient discontinued treatment because of thrombo-
cytopenia (see below) and the echocardiogram was not repeated.
Pulmonary toxicity
As described above, one patient (case 72) died having developed
pulmonary embolism followed by a clinical picture of pneu-
monitis. Two further patients (cases 55 and 57) died suddenly
having developed pneumonia without documented neutropenia
within 1 month ofreceiving BMS-181174, in both cases after three
courses at 75 mg m 2. In one of these cases, post-mortem analysis
showed adenocarcinoma ofthe lung with focal early adult respira-
tory distress syndrome (ARDS).
Among the patients whose LVEF did not change significantly
by the criteria used here, there was one further case of possible
drug-related dyspnoea. A patient who received two courses of
BMS-181174 at 75 mg m-2 developed grade 3 dyspnoea with a
normal chest radiograph. The echocardiogram showed a small
pericardial effusion, with reduction in LVEF to 58% from a base-
line value of 73%.
Nephrotoxicity
Possible renal toxicity was noted in three of 82 patients (4%). This
was manifest as a rise in serum creatinine from the baseline value,
amounting to grade I toxicity in one patient treated at 65 mg m-2and
two cases of grade 2 toxicity, one at 32 mg m-2 and one at
50 mg m-2. The latter (case 47) was a patient with metastatic transi-
tional cell carcinoma of the bladder and unilateral hydronephrosis.
He was treated with two cycles ofBMS-181174 at 50 mg m-3, having
previously received combination chemotherapy including cisplatin.
His serum creatinine before BMS-181174 was borderline at
123 pmol 1-', rising after a second course to a peak of 350 ,umol 1-'.
He had trace haematuria and proteinuria, and chemotherapy was
discontinued. He developed clinical evidence of progressive disease
and died 7 weeks after the second course of BMS-181174. No ante-
mortem or post-mortem renal histology was available.
Symptomatic toxicities
BMS-181 174 caused mild/moderate emesis that was generally
well-controlled with standard antiemetics. Grade 1-2 nausea was
reported by 21 patients including a few patients at all dose levels
>3.2 mg m-2. Moderate or severe emesis (grade 2-3) was experi-
enced by fifteen patients including thirteen treated at 65-
75 mg m-'. One patient experienced a mild allergic reaction with
facial flushing, dizziness and throat dryness/tightness during the
first injection of BMS-181174. The treatment was stopped and the
patient recovered over 1 hour without additional medication.
Response to BMS-181174
Four patients achieved a partial response (PR, reduction in size of
marker lesion(s) to <50% of pretreatment measurement) giving a
response rate of4 out of 82 (5%) (Table 7). Of50 patients treated at
0.8-50 mg m-'BMS-181174, only one (2%) responded, achieving
a PR in liver metastases from colorectal cancer after four courses at
7.5 mg m-2. Of 12 patients treated at 65 mg m-2, there was one
minor response (MR, reduction of 25-50% from baseline) in
pulmonary metastases from colorectal cancer after two courses and
one PR in a patient with ovarian cancer. Both patients had previ-
ously received systemic therapy, with 5-fluorouracil/folinic acid
and platinum-containing chemotherapy respectively. Of20 patients
treated at 75 mg m-', one patient with adenocarcinoma of unknown
primary site achieved PR in pulmonary and liver metastases after
two courses and one patient with non-small-cell lung cancer
achieved PR in lung deposits, again after two courses. Neither of
these patients had prior chemotherapy. Thus the PR rate at 65-
75 mg m-' was 3 out of 32 (9%). Although this was higher than the
rate seen at low dose levels (2% at 0.8-50 mg m-'), there was no
significant difference between response rates in these two treatment
groups (P = 0.29 by Fisher's exact test).
Reasons for stopping treatment, treatment-related
deaths
Of the 82 patients treated, only four (5%) were able to complete
six courses of treatment, at 1.6 mg m-2 (one case), 11.5 mg m-'
(two cases) and 19 mg m-2 (one case). Treatment was discontinued
before completion of six courses because ofprogressive disease in
44 of 50 patients (88%) treated at 0.8-50 mg m-2 (see Table 8). At
65-75 mg m-2, treatment was discontinued for progressive disease
in 22 out of 32 patients (69%) and because oftoxicity in 17 out of
32 (53%). In seven cases, both toxicity and disease progression
were factors in the decision to stop treatment. Non-haematological
toxicities leading to cessation of treatment included grade 3
thrombophlebitis (one case), deep venous thrombosis (i.e. grade 4
thrombophlebitis, two cases), pulmonary toxicity, including pneu-
monitis/pneumonia (three cases), pulmonary embolus (one case),
unexplained dyspnoea (one case), cardiac toxicity (one case), renal
impairment (one), anaphylaxis (one) and declining performance
status (one).
As described above, there were four possible treatment-related
deaths. Three of these showed evidence of pulmonary toxicity.
Two patients (cases 55 and 57) died suddenly with a clinical
picture of pneumonia/pneumonitis, in both cases after three
courses at 65 mg m-2. In a third (case 72), a similar clinical picture
developed after pulmonary embolism possibly related to throm-
bosis around a long line. Finally, one patient with bladder cancer
(case 47) died 7 weeks after a second course of BMS-181174
at 50 mg m-2. There was evidence of progressive disease, but
deteriorating renal failure may have been a contributory factor.
DISCUSSION
For clinical testing, the starting dose was chosen at 0.8 mg m-,
which corresponds to one-third of the TLD in the dog. Preclinical
studies had noted that the dog was more sensitive to this drug than
mice or rats (Nicaise and Usakewicz, 1989). The lack of clinical
activity or haematological toxicity observed in patients treated at
the early dose levels (0.8-7.5 mg m-2) suggested that this dose was
inappropriately low. Pharmacokinetic analysis seemed to confirm
this impression: despite development of a sensitive assay it was
not possible to detect accurately quantifiable levels of the
TEMMC moiety of BMS-181174 in the plasma of patients treated
at the 0.8 and 1.6 mg m-2 dose levels. No pharmacokinetic infor-
mation had been collected in the single-dose toxicity study in
dogs. However, in mice, at the LD1O dose, the pharmacokinetics of
TEMMC were determined and the AUC was 47 646 ng h ml-'
(LaCreta, 1995b). Therefore, the AUC at the LD,W in mice was
British Journal of Cancer (1998) 77(11), 2020-2027 . Cancer Research Campaign 1998Phase I study ofBMS-181174 2027
similar to the AUC at doses ranging from 32 to 75 mg m-2 in
humans. This finding supports the belief that the early doses were
inappropriately low.
The data obtained on patients treated with bolus injections at
11.5-19 mg m-2 showed an estimated T12 of approximately 7 h.
From 32 mg m-2 the mode of administration was changed from
bolus injection to short (30 min) infusion in an attempt to reduce
the risk of thrombophlebitis. Sample analysis indicated that the
pharmacokinetics were linear at doses of 11.5-75 mg m-2, and the
drug appeared to be widely distributed.
The dose-limiting toxicity of BMS-181174 was myelosuppres-
sion. Significant (grade 3-4) myelosuppression necessitating treat-
ment modification was seen at 65 and 75 mg m-2. In general,
neutropenia was less of a problem than thrombocytopenia, which
was frequently prolonged and cumulative. This was the
commonest toxicity necessitating cessation oftreatment in patients
receiving multiple courses of BMS-181174 at 65-75 mg m-2.
Median nadir times for neutropenia were 15-19 days, while nadirs
for thrombocytopenia were later (16-24 days), as observed with
the parent drug MMC (Crooke and Bradner, 1976). At 75 mg m-2
there was a notably higher incidence of grade 3-4 thrombo-
cytopenia in patients previously treated with chemotherapy (83%)
compared with previously untreated patients (21%). There was
also a difference in incidence of grade 3-4 neutropenia: 33% in
pretreated cases compared with 7% untreated. This suggests that
the MTD for chemotherapy-naive patients is 75 mg m-2 and for
pretreated patients 65 mg m-2.
Thrombophlebitis of grades 1-3 was seen in 13% of patients
treated with BMS-181174 at dose levels 0.8-19mg m-2. In an
attempt to ameliorate this, the schedule of administration was
altered from bolus injection to 30-min infusion. Paradoxically, this
may have been at least partly responsible for the more severe
thrombophlebitis seen at higher dose levels. Study ofthe effects of
similar doses of BMS-181174 administered by 6-h infusion have
shown local venous toxicity with thrombophlebitis and venospasm
during the infusion (Planting et al, 1994). None of our patients
were treated via a central line; while this might protect against
peripheral thrombophlebitis, it could increase the risk of central
thrombosis/embolism. Indeed, this contributed to the death of one
of our patients who was treated via a long line. Other side-effects
of BMS-18 1 174 included nausea and vomiting, which was gener-
ally mild and well controlled with standard antiemetics, usually
dexamethasone and metoclopramide.
We observed four cases of serious organ toxicity. There were
three cases of possible drug-induced pneumonitis associated in
each case with rapid clinical deterioration and death. This toxicity
would represent a serious obstacle to further clinical testing of
BMS-181174. There was also evidence of an effect on renal func-
tion. The parent drug MMC is a known cause ofpulmonary fibrosis
and reportedly causes a rise in serum creatinine in 2% of patients.
Haemolytic-uraemic syndrome can occur and is particularly likely
in patients who receive a cumulative dose of over 60 mg (Martino
et al, 1979; Ratanatharathom et al, 1979; Rabadi et al, 1982).
Preclinical studies have shown that BMS-181174 is cardiotoxic in
rats, although not in mice or dogs (Dorr et al, 1992). In our phase I
study we saw some evidence of impairment of cardiac function as
measured by changes in LVEF. In one patient, previous radio-
therapy involving the cardiac field may have contributed to an
increased susceptibility to BMY-related cardiotoxicity. Otherwise
the changes in LVEF were generally mild, asymptomatic,
reversible and with no clear dose relationship.
We were able to demonstrate that BMS-181174 has anti-tumour
activity. Responses were documented amongst previously treated
and untreated patients. The low overall response rate (6%) reflects
the fact that the starting dose was, in retrospect, at least an order of
magnitude too low. At the highest dose levels (65-75 mg m-2)
BMS-181174 achieved responses in cases of colorectal cancer,
ovarian cancer, non-small-cell lung cancer and an adenocarcinoma
ofunknown primary. Thus, the spectrum ofactivity was similar to
that of MMC (Carter and Crooke, 1979). However, the toxicity
profile appeared to be no more favourable than that of the parent
drug, and no phase II studies are planned.
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